Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of “Hold” by Brokerages

Genmab A/S (NASDAQ:GMAB) has been given an average recommendation of “Hold” by the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $45.20.

Several research firms have recently commented on GMAB. BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Friday, September 20th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in the stock. Capital International Investors boosted its stake in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after buying an additional 315,355 shares during the period. Harding Loevner LP grew its holdings in shares of Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after purchasing an additional 85,665 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Genmab A/S by 16.0% in the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after buying an additional 175,292 shares during the last quarter. Finally, DDD Partners LLC bought a new stake in shares of Genmab A/S during the 2nd quarter worth $8,860,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $23.49 on Friday. The company has a market cap of $15.53 billion, a P/E ratio of 19.58, a PEG ratio of 0.73 and a beta of 0.98. Genmab A/S has a fifty-two week low of $23.24 and a fifty-two week high of $35.88. The stock has a 50 day simple moving average of $26.55 and a two-hundred day simple moving average of $27.54.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. On average, research analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.